President Names New NCAB Chair, Three New Members

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

WASHINGTON-President Clinton has named Phillip A. Sharp, PhD, of the Massachusetts Institute of Technology, to serve as chair of the National Cancer Advisory Board (NCAB). Dr. Sharp succeeds J. Michael Bishop, MD, of the University of California, San Francisco. The President has also named three new board members-James O. Armitage, MD, James Harold French, Jr., MD, and Arthur Wesley Nienhuis, MD. The 18-member board advises the President, the Secretary of Health and Human Services, and the director of the National Cancer Institute on the policies and activities of the NCI.

WASHINGTON—President Clinton has named Phillip A. Sharp, PhD, of the Massachusetts Institute of Technology, to serve as chair of the National Cancer Advisory Board (NCAB). Dr. Sharp succeeds J. Michael Bishop, MD, of the University of California, San Francisco. The President has also named three new board members—James O. Armitage, MD, James Harold French, Jr., MD, and Arthur Wesley Nienhuis, MD. The 18-member board advises the President, the Secretary of Health and Human Services, and the director of the National Cancer Institute on the policies and activities of the NCI.

Dr. Armitage is dean of the College of Medicine, University of Nebraska, Omaha. Dr. French is clinical assistant professor of plastic surgery, Georgetown University. Dr. Nienhuis, director, St. Jude Children’s Hospital, was reappointed to the board. He was first named a member in December 1998 to fill a vacant seat.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.